Northwest Biotherapeutics (OTCQB: NWBO) announced that its Chief Technical Officer, Dr. Marnix Bosch, will present survival data on its DCVax-L therapy at the 2026 Annual Meeting of the British Neuro-Oncology Society (BNOS) on July 3.

The presentation, titled "DCVax-L–Associated Survival Extension Assessed Through Propensity Score Matching Analyses," is scheduled for 10:00 a.m. GMT and will examine the association between DCVax-L treatment and patient survival using propensity score matching methodologies.

The company said the slide deck will be posted to its website following the presentation.

DCVax-L is Northwest Biotherapeutics' lead therapy candidate for glioblastoma, an aggressive form of primary brain cancer. The company has completed a 331-patient Phase III trial of the treatment and has submitted a Marketing Authorization Application (MAA) for commercial approval in the United Kingdom, which is currently under regulatory review.